Abstract:Tumor cells are well‐known to have elevated levels of sialylated surface glycoproteins. The addition of sialic acid (a negatively‐charged sugar) to select surface receptors modulates the structure and function of such receptors, leading to changes in intracellular signaling and gene expression. Increased tumor cell sialylation occurs, in part, through the upregulation of sialyltransferases such as ST6GAL1, an enzyme that adds an α2‐6 linked sialic acid to N‐glycosylated proteins. ST6GAL1 is overexpressed in numerous malignancies, including pancreatic ductal adenocarcinoma (PDAC), and high expression correlates with a poor prognosis. Prior work from our group revealed that ST6GAL1 confers a cancer stem cell phenotype, typified by invasiveness and apoptosis‐resistance, through the sialylation‐dependent activation of receptors such as EGFR. In the current investigation we used human Suit2 PDAC cells, as well as two metastatic Suit2 subclones, to show that ST6GAL1 activity promotes tumor progression and metastasis in tumor xenograft models. Moreover, high ST6GAL1 expression in this isogenic cell series induces EGFR activation and epithelial to mesenchymal transition. To complement tumor xenograft experiments, we developed a genetically‐engineered mouse (GEM) model with conditional ST6GAL1 expression in the pancreas (termed, “SC” mice) and crossed this line to the “KC” PDAC model, which expresses oncogenic Kras (KrasG12D) in the pancreas. Mice with dual expression of ST6GAL1 and KrasG12D (”KSC” mice) exhibit greatly accelerated PDAC initiation, progression, and mortality when compared with KC mice. In light of ST6GAL1's known role in conferring stem/progenitor properties, we hypothesized that ST6GAL1 activity contributes to PDAC initiation by fostering acinar to ductal metaplasia (ADM). During ADM, pancreatic acinar cells de‐differentiate into ductal‐like, progenitor cells and acquire greater proliferative potential as well as apoptosis resistance. Cells undergoing ADM are particularly vulnerable to oncogenic transformation. To interrogate whether ST6GAL1 promotes ADM, we compared SC mice with control, wild‐type littermates. Using a variety of analyses and model systems including RNA‐Seq of GEM pancreata, organoid lines derived from GEM pancreata, the canonical 266‐6 ADM cell model, and in vivo model of inflammation‐induced ADM, we determined that high expression of ST6GAL1 in acinar cells imparts an ADM‐like phenotype, as evidenced by the upregulation of stem and ductal genes and downregulation of genes associated with differentiated acinar cells. Furthermore, GEM tissues and organoids with ectopic ST6GAL1 expression display strikingly elevated levels of activated EGFR. Given that activation of EGFR is one the major drivers of ADM, these data suggest a potential mechanism by which ST6GAL1‐mediated sialylation facilitates ADM. Collectively these results point to a critical role for ST6GAL1 in both early and late stages of pancreatic malignancy.

Role of the ST6GAL1 sialyltransferase in regulating ovarian cancer cell metabolism

Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells

Functions of Sialyltransferases in Gynecological Malignancies: a systematic review

Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer

Sialyltransferase St3gal1 Promotes Cell Migration, Invasion, And Tgf-Beta 1-Induced Emt And Confers Paclitaxel Resistance In Ovarian Cancer

The Sialyltransferase ST3GAL6 Influences Homing and Survival in Multiple Myeloma.

ST6GAL1 inhibits metastasis of hepatocellular carcinoma via modulating sialylation of MCAM on cell surface

ST6GALNAC4 Promotes Hepatocellular Carcinogenesis by Inducing Abnormal Glycosylation.

ST3GAL4 promotes tumorigenesis in breast cancer by enhancing aerobic glycolysis

The β-galactoside α2,6-sialyltranferase 1 (ST6GAL1) inhibits the colorectal cancer metastasis by stabilizing intercellular adhesion molecule-1 via sialylation.

Sugt1 Regulates the Progression of Ovarian Cancer Through the Akt/Pi3k/Mtor Signaling Pathway

Exploring the Relationship Between Metabolism and Immune Microenvironment in Osteosarcoma Based on Metabolic Pathways

Differential Expression of ST6GAL1 in the Tumor Progression of Colorectal Cancer.

ST6GAL1 sialyltransferase promotes acinar to ductal metaplasia and pancreatic cancer progression

Hypersialylation of Tumor Cells Promotes Pancreatic Cancer Progression

ST6GAL2 Downregulation Inhibits Cell Adhesion and Invasion and is Associated with Improved Patient Survival in Breast Cancer.

Hypoxia Alters Epigenetic and N-Glycosylation Profiles of Ovarian and Breast Cancer Cell Lines in-vitro

Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment

Elevation of Sulfatides in Ovarian Cancer: an Integrated Transcriptomic and Lipidomic Analysis Including Tissue-Imaging Mass Spectrometry

Adipose microenvironment promotes hypersialylation of ovarian cancer cells

B4GALT5 a sialylation-related genes associated with patient prognosis and immune microenvironment in ovarian cancer and pan-cancer